Real-world outcomes of guselkumab for ulcerative colitis or Crohn's disease
Part of Digestive system clinical trials.
This study tracks how well guselkumab (a biologic medication that blocks IL-23, a protein that drives inflammation) works for moderate-to-severe ulcerative colitis or Crohn's disease in everyday clinical practice. Researchers want to understand long-term benefits and safety in real patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate-to-severe ulcerative colitis or Crohn's disease confirmed by your doctor
- You are about to start guselkumab for the first time (enrollment happens on or before your first injection)
- You have not previously taken other IL-23 inhibitor medications like risankizumab or mirikizumab
- You have tried 4 or fewer previous biologic or advanced IBD treatments
- You are able and willing to sign consent forms and allow your medical records to be reviewed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well guselkumab works in real life for people with moderate-to-severe Crohn's disease or ulcerative colitis. It tracks patients in the UK who start guselkumab as part of their normal care.
This study looks at how well guselkumab works for people with moderate to severe Crohn's disease or ulcerative colitis when used as part of regular treatment. It gathers information from real patients to see how the drug performs outside of a research setting.
This study tests guselkumab, a medication that reduces inflammation in the gut, for people with moderate-to-severe Crohn's disease or ulcerative colitis who haven't previously tried certain similar biologic drugs. The goal is to see how well it works and is tolerated in real-world use.
This study tracks how guselkumab (a biologic medication that reduces inflammation) works in patients with moderate-to-severe ulcerative colitis or Crohn's disease in Saudi Arabia. Researchers want to understand how the medication helps patients in everyday clinical practice, not in a controlled research setting.
This study tracks how well guselkumab (Tremfya) works in real-life for people with inflammatory bowel disease in Germany. If you are starting this treatment, researchers will watch your progress and ask you to fill out simple surveys about your symptoms.
This study tracks how well guselkumab (Tremfya) works in real-world Chinese patients with moderate to severe ulcerative colitis who haven't tried advanced therapies before. It helps doctors understand how the drug performs outside of controlled trials.
Hear when a new Inflammatory Bowel Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.